

PI 3-kinase p85 α (333-430): sc-4016

BACKGROUND

Phosphatidylinositol 3-kinase (PI 3-kinase) is composed of 85 kDa (p85) and 110 kDa (p110) subunits. p85 lacks PI 3-kinase activity and acts as an adapter, coupling p110 to activated protein tyrosine kinase. Two forms of p85 have been described (p85 α and p85 β), each possessing one SH3 and two SH2 domains. Various p110 isoforms have been identified. p110 α and p110 β interact with p85 α , and p110 α has also been shown to interact with p85 β *in vitro*. p110 δ expression is restricted to white blood cells. It has been shown to bind p85 α and p85 β , but it apparently does not phosphorylate these subunits. p110 δ seems to have the capacity to autophosphorylate. p110 γ does not interact with the p85 subunits. It has been shown to be activated by α and β heterotrimeric G proteins.

REFERENCES

1. Skolnik, E.Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., and Schlessinger, J. 1991. Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. *Cell* 65: 83-90.
2. Otsu, M., Hiles, I., Gout, I., Fry, M.J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., and Totty, N. 1991. Characterization of two 85 kDa proteins that associate with receptor tyrosine kinases, middle-T/pp60-src complexes, and PI3-kinase. *Cell* 65: 91-104.
3. Hiles, I.D., Otsu, M., Volinia, S., Fry, M.J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., and Totty, N.F. 1992. Phosphatidylinositol 3-kinase: structure and expression of the 110 kDa catalytic subunit. *Cell* 70: 419-429.
4. Hu, P., Mondino, A., Skolnik, E.Y., and Schlessinger, J. 1993. Cloning of a novel, ubiquitously expressed human phosphatidylinositol 3-kinase and identification of its binding site on p85. *Mol. Cell. Biol.* 13: 7677-7688.
5. Stoyanov, B., Volinia, S., Hanck, T., Rubio, I., Loubtchenkov, M., Malek, D., Stoyanova, S., Vanhaesebrock, B., Dhand, R., and Nurnberg, B. 1995. Cloning and characterization of a G protein-activated human phosphoinositide-3 kinase. *Science* 269: 690-693.
6. Vanhaesebrock, B., Welham, M.J., Kotani, K., Stein, R., Warne, P.H., Zvelebil, M.J., Higashi, K., Volinia, S., Downward, J., and Waterfield, M.D. 1997. p110 δ , a novel phosphoinositide 3-kinase in leukocytes. *Proc. Natl. Acad. Sci. USA* 94: 4330-4335.

SOURCE

PI 3-kinase p85 α (333-430) is expressed in *E. coli* as a 37 kDa tagged fusion protein corresponding to amino acids 333-430 representing the complete amino terminal PI 3-kinase p85 α SH2 domain of human origin.

PRODUCT

PI 3-kinase p85 α (333-430) is purified from bacterial lysates (>98%) by glutathione agarose chromatography and supplied as 50 μ g purified protein in PBS containing 5 mM DTT and 50% glycerol.

Also available in agarose conjugate form; 100 μ g purified PI 3-kinase p85 α (333-430) protein conjugated to 0.1 ml agarose in PBS containing 0.1% azide, 0.1% BSA and 10% glycerol: PI 3-kinase p85 α (333-430) AC: sc-4016 AC.

APPLICATIONS

PI 3-kinase p85 α (333-430) is recommended for the enrichment of PI 3-kinase p85 α associated proteins when used in combination with glutathione agarose (sc-2009).

It is also suitable as a Western blotting control for sc-423 and sc-1637.

STORAGE

Store PI 3-kinase p85 α (333-430): sc-4016 at -20° C and store PI 3-kinase p85 α (333-430) AC: sc-4016 AC at 4° C. Stable for one year from the date of shipment.

RESEARCH USE

For research use only, not for use in diagnostic procedures.